So Tilray jumps more than US$170M on cancer newsTilray announced a trial of medical cannabis in the US to treat patients' horrible side effects from breast cancer chemotherapy.
On that news, TLRY jump more than US$170M in value. Meanwhile, TLT's entire valuation is just over US$20M, net of cash.
Let's be clear TLRY is not attempting to cure breast cancer. And from the NR, it's not evident whether TLRY is tackling the issue at the cannabinoid molecular level. That in turn raises question about the precision of their therapies, not to mention delivery systems.
Meanwhile, TLT has kicked off a Ph2 pivotal trial that should validate the Ph1b success of its ACTUAL CURE FOR NMIBC.
So is a real potential cure for cancer worth that much less than a treatment for its side effects?
You be the judge!